Response to comments from the International Patient Organization for Primary Immunodeficiencies on 'Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low- and middle-income countries'

Thierry Burnouf^{1

2}, Jay Epstein³, Jean-Claude Faber⁴, W Martin Smid⁵

Affiliations

¹ Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
² International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
³ McLean, Virginia, USA.
⁴ Association Luxembourgeoise des Hémophiles, Luxembourg City, Luxembourg.
⁵ Sanquin Consulting Services, Amsterdam and Academic Institute IDTM, Groningen, The Netherlands.

Thierry Burnouf et al. Vox Sang. 2024 Sep.

. 2024 Sep;119(9):1023-1024.

doi: 10.1111/vox.13695. Epub 2024 Jun 18.

Thierry Burnouf^{1

2}, Jay Epstein³, Jean-Claude Faber⁴, W Martin Smid⁵

¹ Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
² International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
³ McLean, Virginia, USA.
⁴ Association Luxembourgeoise des Hémophiles, Luxembourg City, Luxembourg.
⁵ Sanquin Consulting Services, Amsterdam and Academic Institute IDTM, Groningen, The Netherlands.

No abstract available

References

1. Elalfy M, Reda M, Elghamry I, Elalfy O, Meabed M, el‐Ekiaby N, et al. A randomized multicenter study: safety and efficacy of mini‐pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1‐18 years with immune thrombocytopenia. Transfusion. 2017;57:3019–3025.
1. Burnouf T, Radosevich M. Nanofiltration of plasma‐derived biopharmaceutical products. Haemophilia. 2003;9:24–37.
1. World Health Organization. Medical Product Alert N°3/2022: Falsified Intratect (human normal immunoglobulin). Falsified Intratect (human normal immunoglobulin) identified in the WHO Regions of the Americas, Eastern Mediterranean and South‐East Asia. Available from: https://www.who.int/news/item/27-05-2022-medical-product-alert-n-3-2022-.... Last accessed 21 May 2024.
1. Bekele B, Masresha Z, Alemayehu M, Seyoum B, Wassie L, Abebe M. Intravenous immunoglobulin G (IVIG) need assessment survey toward local manufacturing of IVIG using a mini‐pool plasma fractionation technique. Health Serv Insights. 2023;16:11786329231157467.
1. El‐Ekiaby M, Goubran HA, Radosevich M, Abd‐Allah A, El‐Ekiaby A, Burnouf T. Pharmacokinetic study of minipooled solvent/detergent‐filtered cryoprecipitate factor VIII. Haemophilia. 2011;17:e884–e888.